Novel oncologic drugs: What they do and how they affect images

Radiographics

Volumn 31, Issue 7, 2011, Pages 2059-2091

  Figueiras, Roberto García ^a   Padhani, Anwar R ^b   Goh, Vicky J ^c   Vilanova, Joan C ^d   González, Sandra Baleato ^a   Martín, Carmen Villalba ^a   Caamaño, Antonio Gómez ^a   Naveira, Anaberta Bermúdez ^a   Choyke, Peter L ^e  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HOSPITAL SANTA CATERINA   (Spain)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ARTICLE; DIAGNOSTIC IMAGING; HUMAN; METHODOLOGY; NEOPLASM; PROGNOSIS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 81255184673     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.317115108     Document Type: Article

References (103)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-674.
2. Hait WN, Hambley TW. Targeted cancer therapeutics. Cancer Res 2009;69(4):1263-1267; discussion 1267.
3. Seufferlein T, Ahn J, Krndija D, Lother U, Adler G, von Wichert G. Tumor biology and cancer therapy: an evolving relationship. Cell Commun Signal 2009; 7:19.
4. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35(4):309-321.
5. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-2049.
6. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010;2(2):165-175.
7. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82(10):699-757.
8. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007;17(4):861-872.
9. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96(8): 1159-1165.
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 (suppl 1):2-10.
11. Semenza GL. A new weapon for attacking tumor blood vessels. N Engl J Med 2008;358(19):2066- 2067.
12. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358(11): 1160-1174.
13. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007;357(1): 39-51.
14. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009;10(12):1179-1187.
15. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tu-morigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
16. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11(1-2):32-50.
17. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008;5(2):102-111.
18. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 2011 Feb 16. [Epub ahead of print]
19. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572-583.
20. Suzuki C, Jacobsson H, Hatschek T, et al. Radio-logic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
22. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195(2):281-289.
23. Tuma RS. Sometimes size doesn't matter: reevalu-ating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006;98(18):1272-1274.
24. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009;72(3):217-238.
25. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25(13):1760-1764.
26. Padhani AR, Koh DM. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011;19(1):181-209.
27. O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging bio-markers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008;9(8):766-776.
28. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007;24(6):1172-1185.
29. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol 2010;65(7):500-516.
30. Gallagher FA. An introduction to functional and molecular imaging with MRI. Clin Radiol 2010;65 (7):557-566.
31. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009;50(Suppl 1):97S-105S.
32. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-2344.
33. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-1478.
34. Gillies RJ, Anderson AR, Gatenby RA, Morse DL. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol 2010;65(7):517-521.
35. Bayouth JE, Casavant TL, Graham MM, Sonka M, Muruganandham M, Buatti JM. Image-based biomarkers in clinical practice. Semin Radiat Oncol 2011;21(2):157-166.
36. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006; 24(20):3299-3308.
37. Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol 2009;193 (2):304-313.
38. Jeswani T, Padhani AR. Imaging tumour angiogen-esis. Cancer Imaging 2005;5:131-138.
39. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005;30(3):324-341.
40. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76(spec no 1):S87-S91.
41. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010;37(suppl 1):S164-S182.
42. Petralia G, Bonello L, Viotti S, Preda L, d'Andrea G, Bellomi M. CT perfusion in oncology: how to do it. Cancer Imaging 2010;10:8-19.
43. Miles KA. Molecular imaging with dynamic contrast-enhanced computed tomography. Clin Radiol 2010;65(7):549-556.
44. Deshpande N, Pysz MA, Willmann JK. Molecular ultrasound assessment of tumor angiogenesis. An-giogenesis 2010;13(2):175-188.
45. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009;100(6): 865-869.
46. Goh V, Padhani AR. Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Ab-dom Imaging 2006;31(2):194-199.
47. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neo-plasia 2009;11(2):102-125.
48. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008;5(4):220-233.
49. Afaq A, Andreou A, Koh DM. Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 2010;10(spec no A):S179-S188.
50. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8(4):259-267.
51. Koh DM, Blackledge M, Collins DJ, et al. Repro-ducibility and changes in the apparent diffusion coeffcients of solid tumours treated with combre-tastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009;19 (11):2728-2738.
52. Sun YS, Cui Y, Tang L, et al. Early evaluation of cancer response by a new functional biomarker: apparent diffusion coeffcient. AJR Am J Roent-genol 2011;197(1):W23-W29.
53. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11(2): 85-95.
54. Patel CN, Goldstone AR, Chowdhury FU, Scars-brook AF. FDG PET/CT in oncology: "raising the bar." Clin Radiol 2010;65(7):522-535.
55. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S-150S.
56. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fuorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773-1782.
57. Nanni C, Fantini L, Nicolini S, Fanti S. Non FDG PET. Clin Radiol 2010;65(7):536-548.
58. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011;8(4):233-242.
59. Kwock L, Smith JK, Castillo M, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006;7(10):859-868.
60. Pinker K, Stadlbauer A, Bogner W, Gruber S, Helbich TH. Molecular imaging of cancer: MR spectroscopy and beyond. Eur J Radiol 2010 May 27. [Epub ahead of print]
61. Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of response to targeted treatment in cancer cells. NMR Biomed 2011;24 (6):648-672.
62. Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coeffcient values and tumor proliferation. J Magn Reson Imaging 2009; 29(6):1360-1366.
63. Denny WA. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol 2010; 6(3):419-428.
64. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010;11(1): 92-102.
65. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivas-cular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21(15):2831-2842.
66. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angio-genesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13 (12):3449-3459.
67. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62.
68. Jain RK, Duda DG, Clark JW, Loeffer JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40.
69. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008;7(1): 71-78.
70. Ng CS, Raunig DL, Jackson EF, et al. Repro-ducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 2010;194(2):W134-W140.
71. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? Radiology 2007;242(3): 777-782.
72. Jain RK, Duda DG, Willett CG, et al. Biomark-ers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6(6):327-338.
73. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008;5(11):634-644.
74. Rieger J, Bähr O, Ronellenftsch MW, Steinbach J, Hattingen E. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? J Clin Oncol 2010;28(27):e477; author reply e478.
75. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer 2010;102(1):1-7.
76. Azad NS, Annunziata C, Barrett T, et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results [abstr]. J Clin Oncol 2007;25(18 suppl):3542.
77. Honer M, Ebenhan T, Allegrini PR, et al. Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Transl Oncol 2010;3(4):264-275.
78. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of er-lotinib or geftinib in patients with acquired resistance to erlotinib or geftinib followed by the addition of everolimus. Clin Cancer Res 2007;13(17): 5150-5155.
79. Atkinson DM, Clarke MJ, Mladek AC, et al. Using fuorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xe-nografts. Head Neck 2008;30(6):790-799.
80. Mishani E, Abourbeh G. Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007;7(18):1755-1772.
81. Sohn HJ, Yang YJ, Ryu JS, et al. [18F]Fluorothy-midine positron emission tomography before and 7 days after geftinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14(22):7423-7429.
82. Ma BB, Leung SF, Kam MK, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiation therapy (IMRT) in lo-coregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) [abstr]. J Clin Oncol 2008;26(Suppl):6055.
83. Lind JS, Meijerink MR, Dingemans AM, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 2010;20(12):2890-2898.
84. Tufman A, Huber RM. Biological markers in lung cancer: a clinician's perspective. Cancer Biomark 2010;6(3-4):123-135.
85. Ma WW, Jacene H, Song D, et al. [18F]fuorode-oxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27(16):2697-2704.
86. Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug effcacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 2010;51(10):1559-1564.
87. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangio-genic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15 (5):1612-1622.
88. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39(14):2012-2020.
89. Tang L, Zhang XP, Sun YS, et al. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coeffcient in the evaluation of therapy response in patients. Radiology 2011;258 (3):729-738.
90. Alonzi R, Padhani AR, Taylor NJ, et al. Antivas-cular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 2011;80(3):721-727.
91. Nemoto K, Tateishi T, Ishidate T. Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results. Urol Int 2010;85(4):421-426.
92. Mueller-Lisse UG, Swanson MG, Vigneron DB, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46(1):49-57.
93. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009;113(3):509-517.
94. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med 2007;13(7):287-297.
95. Jordan BF, Runquist M, Raghunand N, et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvi-ronment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005;7(5):475-485.
96. Rudin M. Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol 2007;17(10): 2441-2457.
97. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102(1):8-18.
98. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24(20):3293-3298.
99. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010;256 (2):348-364.
100. Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol 2010;11(6):589-595.
101. Padhani AR. Multifunctional MR imaging assessment: a look into the future. In: Koh DM, Thoeny HC, eds. Diffusion-weighted MR imaging. Berlin, Germany: Springer, 2010; 165-180.
102. Miles KA, Williams RE. Warburg revisited: imaging tumour blood fow and metabolism. Cancer Imaging 2008;8:81-86.
103. Dizdarevic S, Peters AM. Imaging of multidrug resistance in cancer. Cancer Imaging 2011;11:1-8.